Article
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2016
Asselah Tarik, Boyer Nathalie, Saadoun David, Martinot-Peignoux Michele, Marcellin Patrick
Abstract excerpt
There has been a revolution in the treatment of chronic hepatitis C. Several oral regimens combining direct-acting antivirals (DAAs) from different families [NS5B nucleotide inhibitors, NS5B non-nucleoside inhibitors, NS5A replication complex inhibitors and NS3/4A protease inhibitors (PI)] have been developed. These regimens result in an increase in sustained virological response (SVR) rates to above 90% and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.